Integrating these structural insights with functional validation, we engineered a dual-expression recombinant vaccinia virus targeting both PD-1 and FilC to enhance immune-mediated tumor clearance in HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.